Breaking
DeepMind Blog Introducing Google Antigravity 2.0 Phys.org Expedition to Antarctica advances research on potential melanoma treatment Autocar New Vauxhall Astra confirmed by 2030 with less "traditional" shape Electrek Donut Lab’s ‘solid-state’ battery exposed as regular li-ion in damning investigation CNBC Business Italian coffee giant Lavazza launches single-serve tablets to make espresso in the U.S.
Breaking
DeepMind Blog Introducing Google Antigravity 2.0 Phys.org Expedition to Antarctica advances research on potential melanoma treatment Autocar New Vauxhall Astra confirmed by 2030 with less "traditional" shape Electrek Donut Lab’s ‘solid-state’ battery exposed as regular li-ion in damning investigation CNBC Business Italian coffee giant Lavazza launches single-serve tablets to make espresso in the U.S.
Nature Medicine

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

Jing L. Marantz 2026-06-08 · Science
myndfocal
Nature Medicine, Published online: 08 June 2026; doi:10.1038/s41591-026-04440-4 In the phase 2 EMBRAZE study, participants receiving tirzepatide and apitegromab lost less lean mass compared to participants receiving tirzepatide and placebo.

Nature Medicine, Published online: 08 June 2026;

doi:10.1038/s41591-026-04440-4

In the phase 2 EMBRAZE study, participants receiving tirzepatide and apitegromab lost less lean mass compared to participants receiving tirzepatide and placebo.

— Source: Nature Medicine (https://www.nature.com/articles/s41591-026-04440-4)

Science
Read original on Nature Medicine →